SCHEMBL21035524

SCHEMBL21035524

NC1CC2CCC(C1)C2C(=O)[C@@H]1C[C@H](Oc2ccccc2)CN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.38
MMP1 P03956 4/20 0.38
MMP3 P08254 4/20 0.38
MMP9 P14780 2/20 0.38
ADAM17 P78536 1/20 0.38
AKR1C3 P42330 4/20 0.38
AKR1C1 Q04828 1/20 0.37
USP5 P45974 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
HTR2C P28335 1/20 0.35
MMP7 P09237 3/20 0.35
GHSR Q92847 3/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
EIF2AK3 Q9NZJ5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21035658 0.90 GHSR (0.39) MMP9AKR1C3AKR1C1HCRTR1HCRTR2
SCHEMBL21034976 0.90 GHSR (0.39) MMP9AKR1C3AKR1C1HCRTR1HCRTR2
SCHEMBL21035523 0.86 AKR1C3 (0.43) KAT6AMMP1MMP3MMP9ADAM17
SCHEMBL21035522 0.82 MMP1 (0.43) KAT6AMMP1MMP3MMP9ADAM17
SCHEMBL21035353 0.82 GHSR (0.43) MMP1MMP3MMP9ADAM17AKR1C3
SCHEMBL21034980 0.82 GHSR (0.43) MMP1MMP3MMP9ADAM17AKR1C3
SCHEMBL21035346 0.81 CA12 (0.48) MMP1MMP3MMP9ADAM17AKR1C3
SCHEMBL21034984 0.81 CA12 (0.48) MMP1MMP3MMP9ADAM17AKR1C3
SCHEMBL21035399 0.78 HTR1A (0.44) MMP1MMP3MMP9ADAM17AKR1C3
SCHEMBL21035314 0.78 HTR1A (0.44) MMP1MMP3MMP9ADAM17AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed